USA - engelska - NLM (National Library of Medicine)

amneal pharmaceuticals ny llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   erythromycin delayed-release tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes or streptococcus pneumoniae . listeriosis caused by listeria monocytogenes . respiratory tract infections due to mycoplasma pneumoniae . skin and skin structure infections of mild to moderate severity caused by streptococcus pyogenes or staphylococcus aureus (resistant staphylococci may emerge during treatment). pertussis (whooping cough) caused by bordetella pertussis . erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. diphtheria: infections due to corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum . intestinal amebiasis caused by entamoeba histolytica (oral erythromycins only). extraenteric amebiasis requires treatment with other agents. acute pelvic inflammatory disease caused by neisseria gonorrhoeae : erythromycin lactobionate for injection, usp followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by n. gonorrhoeae in female patients with a history of sensitivity to penicillin. patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. erythromycin delayed-release tablets are indicated for treatment of the following infections caused by chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. when tetracyclines are contra-indicated or not tolerated, erythromycin delayed-release tablets are indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to chlamydia trachomatis . when tetracyclines are contraindicated or not tolerated, erythromycin delayed-release tablets are indicated for the treatment of nongonococcal urethritis caused by ureaplasma urealyticum . primary syphilis caused by treponema pallidum . erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. legionnaires’ disease caused by legionella pneumophila . although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires’ disease. prophylaxis prevention of initial attacks of rheumatic fever penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis)1 . erythromycin delayed-release tablets are indicated for the treatment of penicillin-allergic patients. the therapeutic dose should be administered for ten days. prevention of recurrent attacks of rheumatic fever penicillin or sulfonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the american heart association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever)1 . erythromycin is contraindicated in patients with known hypersensitivity to this antibiotic. erythromycin is contraindicated in patients taking terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (see precautions - drug interactions ). do not use erythromycin concomitantly with hmg coa reductase inhibitors (statins) that are extensively metabolized by cyp 3a4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - erythromycin ethyl succinate -

Malta - engelska - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - erythromycin - powder for solution for infusion - erythromycin 1000 mg - antibacterials for systemic use

Storbritannien - engelska - myHealthbox

milpharm limited - erythromycin ethylsuccinate - granules for oral suspension - 125mg/5ml - for the prophylaxis and treatment of infections caused by erythromycin sensitive organisms and in the treatment of a great variety of clinical infections

Storbritannien - engelska - myHealthbox

milpharm limited - erythromycin ethylsuccinate - granules for oral suspension - 250mg/5ml - for the prophylaxis and treatment of infections caused by erythromycin sensitive organisms and in the treatment of a great variety of clinical infections

Storbritannien - engelska - myHealthbox

milpharm limited - erythromycin ethylsuccinate - granules for oral suspension - 500mg/5ml - for the prophylaxis and treatment of infections caused by erythromycin sensitive organisms. erythromycin is highly effective in the treatment of a great variety of clinical infections

USA - engelska - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d), benzoyl peroxide (unii: w9wzn9a0gm) (benzoyl peroxide - unii:w9wzn9a0gm) - erythromycin 30 mg in 1 g - erythromycin and benzoyl peroxide topical gel usp is indicated for the topical treatment of acne vulgaris. erythromycin and benzoyl peroxide topical gel usp is contraindicated in those individuals who have shown hypersensitivity to any of its components.

USA - engelska - NLM (National Library of Medicine)

padagis israel pharmaceuticals ltd - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 20 mg in 1 ml - erythromycin topical solution usp, 2% is indicated for the topical treatment of acne vulgaris. erythromycin topical solution usp, 2% is contraindicated in those individuals who have shown hypersensitivity to any of its components.

USA - engelska - NLM (National Library of Medicine)

blenheim pharmacal, inc. - erythromycin stearate (unii: lxw024x05m) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythrocin stearate filmtab tablets and other antibacterial drugs, erythrocin stearate filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythrocin stearate tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the e

USA - engelska - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg